August 2024 in “JAAD Case Reports” Upadacitinib successfully regrew hair in a child with alopecia universalis and specific genetic mutations.
February 2026 in “Dermatology and Therapy” Sonidegib is effective and safe for treating advanced basal cell carcinoma, but biopsies are needed to confirm tumor clearance.
January 2023 in “Journal of The American Academy of Dermatology” Baricitinib helped most teenagers with severe hair loss regrow hair and had mild side effects.
January 2013 in “Shiyong yixue zazhi” Astraglus polysaccharide may help hair growth by boosting follicle stem cell activity.
3 citations
,
May 2022 in “Clinical and experimental dermatology” Drugs targeting EMT molecules show promise for treating lichen planopilaris.
1 citations
,
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.
April 2019 in “Journal of the Endocrine Society” A woman's severe insulin resistance improved with treatment, but she still had high testosterone levels due to ovarian issues.
July 2025 in “Journal of Investigative Dermatology” Baricitinib stops hair loss and promotes regrowth in alopecia areata.
April 2025 in “Anais Brasileiros de Dermatologia” Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.
November 2025 in “Mendeley Data” Standard dosing is more effective for severe alopecia areata in children, but unorthodox dosing can be safe and considered if needed.
12 citations
,
September 2019 in “BioFactors” Ginkgolide B and bilobalide help mink hair grow by making skin cells healthier and boosting a key growth protein.
May 2023 in “International Journal of Trichology” Tofacitinib may be an effective and safe treatment for hair loss in teenagers with alopecia areata.
18 citations
,
January 2021 in “Theranostics” The targeted nanohybrids effectively reduced psoriasis symptoms and improved skin health.
Cetirizine-loaded gel may effectively promote hair growth in alopecia.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib helps long-term hair regrowth in severe alopecia areata patients.
1 citations
,
October 2023 in “Clinical, cosmetic and investigational dermatology” Tofacitinib improved hair loss and skin symptoms in a patient after secukinumab caused hair loss.
8 citations
,
July 2020 in “Dermatologic Therapy” Tofacitinib may effectively treat folliculitis decalvans.
September 2023 in “International Journal of Applied Pharmaceutics” The formulated gel is a promising treatment for alopecia areata.
2 citations
,
September 2022 in “Dermatologic Therapy” Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.
9 citations
,
December 2014 in “British Journal of Dermatology” Hedgehog pathway inhibitors used for skin cancer can cause significant hair loss, which may improve after stopping the medication.
8 citations
,
January 2013 in “Medicinal chemistry” The compound 4c showed strong potential as an anticancer agent.
16 citations
,
August 2023 in “JAAD Case Reports” JAK inhibitors, like ruxolitinib, may effectively treat frontal fibrosing alopecia.
2 citations
,
April 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
July 2025 in “Journal of Investigative Dermatology” Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.
288 citations
,
January 2001 in “Journal of Biological Chemistry” Tgm2 helps stabilize dying cells and aids fibroblast attachment to the extracellular matrix.
January 2017 in “The American Pharmacists Association eBooks” January 2017 in “The American Pharmacists Association eBooks”
April 2023 in “Journal of Investigative Dermatology” Treprostinil, a drug, can delay wound healing in healthy cells but doesn't affect diabetic foot ulcer cells, suggesting further research could help understand its role in treating these ulcers.
May 2025 in “Journal of Inflammation Research” A combination of ixekizumab and tofacitinib successfully treated severe scalp cellulitis, leading to hair regrowth.
42 citations
,
April 2012 in “Seminars in Oncology” Targeted cancer therapies often cause skin problems that need careful management to improve patient quality of life and treatment success.